- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03433950
Clinical Characteristics of Parkinson's Disease Subjects With Severe Hypertension During Motor OFFs. (CLIN-HTN-PD)
15. november 2021 opdateret af: Kathryn Anne Chung, Oregon Health and Science University
Current management of hypertension in PD motor fluctuators is flawed.
The current practice often is to treat transient hypertensive spikes reported by patients or measured in clinics with anti-hypertensive medications.
This may contribute to morbidity by worsening orthostatic hypotension and increasing fall risk.
There is a scarcity of literature on this subject and there is no documentation of severe hypertension with rises in systolic blood pressure exceeding 50% of baseline occurring during motor "OFF".
There are two studies that have demonstrated that blood pressure fluctuation can occur in motor fluctuators during the "OFF" state1,2.
The study by Baratti et al measured blood pressure in 13 Parkinson's disease patients, 7 with motor fluctuations and 6 without fluctuations.
In the fluctuators, the mean systolic/diastolic blood pressures were significantly higher than the non-fluctuators during the "OFF" state but not the "ON" state.
Studieoversigt
Status
Suspenderet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is an observational study.
This study will only recruit Parkinson's subjects with rises in systolic blood pressure exceeding 50% of baseline during motor off periods to select for subjects with severe blood pressure fluctuations.
The clinical characteristics, including but not limited to, the degree of change of the motor tapping score, during an "off" period of this group of subjects with severe hypertension.
There is a screening visit, a at home monitoring period, and a one-time 4-8 hour study visit for subjects that satisfy the inclusion criteria.
The screening visit will assess Parkinson's motor state and review the inclusion/exclusion criteria.
The at home monitoring period will measure blood pressure twice a levodopa cycle for 5 cycles (for most subjects, this will be for two days and is dependent on the subject's clinical levodopa cycle).
Measurements will occur pre-levodopa dose (the maximal "OFF" time), and half-way through the cycle (maximal "ON" time).
The percentage of change will be calculated and those that have a systolic change of greater than or equal to 50% will proceed to the outpatient visit.
The outpatient visit will measure blood pressure, pulse, Parkinson's motor symptoms, and plasma levodopa levels.
Undersøgelsestype
Observationel
Tilmelding (Forventet)
10
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- VA Portland Health Care System
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 99 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Parkinson's disease participants with motor fluctuations.
Beskrivelse
Inclusion Criteria:
- Idiopathic Parkinson's disease fulfilling UK Brain Bank clinical criteria.
- Treatment with chronic levodopa (levodopa treatment for ≥ 3 years).
- Rise in "OFF" systolic blood pressure exceeding 50% of baseline "ON" systolic blood pressure as shown by at home monitoring.
- History of "wearing off" prior to 4 hours after the previous levodopa dose per patient report or chart documentation.
Exclusion Criteria:
- Daily beta-blocker therapy.
- Diabetes mellitus, autonomic neuropathy, or other condition known to alter autonomic functions.
- Significant cognitive impairment as measured by the Montreal Cognitive Assessment score of < 16
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Fluctuator
Parkinson's subjects with rises in systolic blood pressure exceeding 50% of baseline during motor off periods to select for subjects with severe blood pressure fluctuations.
|
Observational
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Systolic Blood Pressure Change
Tidsramme: Change in systolic blood pressure from 08:30 am measurement to 11:00 am measurement.
|
Blood pressure measurement taken at lowest "OFF" rating on the Unified Parkinson's Disease Rating Scale (UPDRS) and highest "ON" rating on the UPDRS.
|
Change in systolic blood pressure from 08:30 am measurement to 11:00 am measurement.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Diastolic Blood Pressure Change
Tidsramme: Change in systolic blood pressure from 08:30 am measurement to 11:00 am measurement.
|
Blood pressure measurement taken at lowest "OFF" rating on the Unified Parkinson's Disease Rating Scale (UPDRS) and highest "ON" rating on the UPDRS.
|
Change in systolic blood pressure from 08:30 am measurement to 11:00 am measurement.
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Baratti M, Calzetti S. Fluctuation of arterial blood pressure during end-of-dose akinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1984 Nov;47(11):1241-3. doi: 10.1136/jnnp.47.11.1241.
- Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology. 1993 Dec;43(12 Suppl 6):S23-7.
- Pursiainen V, Korpelainen JT, Haapaniemi TH, Sotaniemi KA, Myllyla VV. Blood pressure and heart rate in parkinsonian patients with and without wearing-off. Eur J Neurol. 2007 Apr;14(4):373-8. doi: 10.1111/j.1468-1331.2007.01672.x.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
6. februar 2018
Primær færdiggørelse (Forventet)
31. december 2022
Studieafslutning (Forventet)
31. december 2022
Datoer for studieregistrering
Først indsendt
8. januar 2018
Først indsendt, der opfyldte QC-kriterier
8. februar 2018
Først opslået (Faktiske)
15. februar 2018
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
16. november 2021
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
15. november 2021
Sidst verificeret
1. november 2021
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 17490
- VA IRB 4143 (Anden identifikator: VA Portland Health System)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Forhøjet blodtryk
-
VIVUS LLCIkke rekrutterer endnuPulmonal arteriel hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension (PAH) | Pulmonal arteriel hypertension WHO gruppe I | Pulmonal arteriel hypertension PAH
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyIkke rekrutterer endnu
-
BayerAfsluttet
-
National Taiwan University Hospital Hsin-Chu BranchRekrutteringHypertension, essentiel | Hypertension, maskeretTaiwan
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc...Ikke rekrutterer endnuPulmonal hypertension | Pulmonal arteriel hypertension (PAH)Forenede Stater
-
BackBeat Medical IncIkke rekrutterer endnuHypertension, systolisk | Hypertension (HTN) | Hjertesvigt med bevaret ejektionsfraktion (HFpEF)Georgien
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Forenede Stater
-
University of Sao Paulo General HospitalRekrutteringPulmonal arteriel hypertension (PAH)Brasilien
-
University Hospital, BrestIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Frankrig
-
Shanghai Zhongshan HospitalIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)
Kliniske forsøg med No Intervention
-
Otsuka Pharmaceutical Factory, Inc.CelerionAfsluttet
-
Seoul National University HospitalSamsung Medical Center; Chosun University HospitalAfsluttetRadiofrekvensablation | Mikrobølge-ablationKorea, Republikken
-
University of MinnesotaAfsluttet
-
University of SalernoAzienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'AragonaRekruttering
-
Ahram Canadian UniversityRekruttering
-
University of MinnesotaRekruttering
-
China National Center for Cardiovascular DiseasesAktiv, ikke rekrutterende
-
Assistance Publique - Hôpitaux de ParisAfsluttetSeglcellesygdomFrankrig
-
Swiss Federal Institute of TechnologyInstituto de Investigação em ImunologiaAfsluttetForstyrrelser i jernmetabolisme | Overbelastning af jern | PolyfenolerPortugal, Schweiz